CD163 and chronic obstructive pulmonary disease: A clinical study using the M2 marker CD163 examined bronchoalveolar lavage (BAL) from 114 COPD patients, including 72 current smokers and 42 ex-smokers who had quit smoking for an average of 3.5 years.